Results 91 to 100 of about 18,145 (196)

Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab

Clinical Ophthalmology, 2011
Christina Antonopoulos1, Maxwell Stem2, Grant M Comer21Department of Ophthalmology, Boston University, Boston, MA, USA; 2WK Kellogg Eye Center, Department of Ophthalmology, University of Michigan, Ann Arbor, MI, USAPurpose: Previous reports have ...
Antonopoulos C, Stem M, Comer GM
doaj  

Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.

PLoS ONE, 2014
PurposeIt is known that endothelial cells in the kidney are also strongly VEGF-dependent. Whether intravitreal drugs can be detected within the glomeruli or affect VEGF in glomerular podocytes is not known.
Alexander Tschulakow, Sarah Christner, Sylvie Julien, Maximilian Ludinsky, Markus van der Giet, Ulrich Schraermeyer   +5 more
doaj   +1 more source

Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB®) versus Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study [PDF]

Parth J Rana,1 Himanshu Deshmukh,2 Urmil Shah,3 Vinod Kumar,4 Sanghamitra Kanungo,5 Deepika Singhal,6 Santosh Kumar Mahapatra,7 Ira Vakharia,8 Mukesh Jaiswal,9 Ajitkumar Gondane,10 Pooja Vaidya,10 Vinayaka Shahavi,9 Harish Shandilya,11 Dattatray Pawar,10
Kumar V, Gondane A, Shahavi V, Shandilya H, Rana PJ, Vakharia I, Pawar D, Singhal D, Mahapatra SK, Jaiswal M, Sharma A, Deshmukh H, Shah U, Vaidya P, Kanungo S   +14 more
core  

Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. [PDF]

, 2015
INTRODUCTION: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease. METHODS: Prospective, interventional, case series. All patients underwent
Battaglia Parodi, M, Parodi MB, Iacono P, Munk MR, Munk, Marion, BANDELLO , FRANCESCO, Iacono, P, Bandello, F   +7 more
core   +1 more source

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration

, 2010
Tryfon Rotsos, Praveen J Patel, Fred K Chen, Adnan TufailMedical Retina Service, Moorfields Eye Hospital, London, UKPurpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration ...
Praveen J Patel, Fred K Chen, et al, null patel, Tryfon Rotsos   +4 more
core   +1 more source

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials

, 2019
Qingquan Wei,1,2,* Rui Chen,1,2,* Qiyang Lou,1,2 Jing Yu1,2 1Department of Ophthalmology, Ninghai First Hospital, Zhejiang 315600, People’s Republic of China; 2Department of Ophthalmology, Shanghai Tenth People’s Hospital Affiliated with ...
Lou Q, Wei Q, Yu J, Chen R
core  

Mean change in central macular thickness from baseline: (A) Ranibizumab versus laser, (B) Ranibizumab combined with laser versus laser, and (C) Ranibizumab combined with laser versus ranibizumab.

, 2014
RBZ  =  ranibizumab, RBZ + Laser  =  ranibizumab combined with laser; SD  =  standard deviation; IV  =  inverse variance; CI  =  confidence interval.
Yuhua Tong (513824), Wensheng Li (309393), Fangzheng Jiang (513822), Sihong Mao (513823), Guohai Chen (65113), Radouil Tzekov (309387)   +5 more
core   +1 more source

Ranibizumab for the treatment of degenerative ocular conditions

, 2014
Magdalini Triantafylla,1 Horace F Massa,2 Doukas Dardabounis,1 Zisis Gatzioufas,2 Vassilios Kozobolis,1 Konstantinos Ioannakis,1 Irfan Perente,1,3 Georgios D Panos1,21Department of Ophthalmology, University General Hospital of Alexandroupolis, School of ...
Gatzioufas Z, Kozobolis V, Massa HF, Triantafylla M, Dardabounis D, Panos GD, Ioannakis K, Perente I   +7 more
core  

CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study [PDF]

Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Subhendu Boral,1 Arnab Das,2 Soumava Mandal,4 Ranabir Bhattacharya,1 Shouvick Dan,1 Dinesh Rungta1 1Department of Vitreoretinal Services, Disha Eye ...
Mandal S, Chakraborty D, Sinha S, Biswas RK, Bhattacharya R, Maiti A, Boral S, Das A, Sinha TK, Rungta D, Dan S   +10 more
core  

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

, 2009
Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of ...
Efstratios Parikakis, Ioannis D Ladas, Dimitrios A Karagiannis, et al.   +3 more
core